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The  insulin-like  growth  factors (IGFs) I and I1 exert 
pleiotropic  effects on diverse  cell  types  through  inter- 
action  with  specific  high affinity cell surface  receptors 
and  with locally produced  binding  proteins. In skeletal 
muscle and  in myoblast cell  lines,  the  functions of IGF- 
I and -11 are complex. Both growth factors appear 
capable of stimulating  cellular  proliferation  and  dif- 
ferentiation, as well as exerting  insulin-like  effects  on 
intermediary metabolism. We have  demonstrated re- 
cently that  the expression of IGF-I1 and  its  receptor is 
induced during  the  terminal  differentiation of the myo- 
blast  cell  line, C2, and  have suggested that IGF-I1 may 
be an autocrine  growth  factor  in  these  cells  (Tollefsen, 
S .  E., Sadow, J. L., and Rotwein, P. (1989) Proc.  Natl. 
Acad. Sci. U. S. A. 86, 1543-1547). We now have  ex- 
amined this cell line  for  expression f other components 
involved  in IGF signaling. The  synthesis of IGF-I is 
low during myoblast proliferation; IGF-I mRNA can 
be detected only through use of a sensitive solution 
hybridization assay. Typical IGF-I receptors can be 
measured in myoblasts, whereas IGF binding  proteins 
cannot  be  detected  in  proliferating  cells or in  condi- 
tioned culture medium. During myogenic differentia- 
tion, IGF-I mRNA levels  increase  transiently by 6-10- 
fold within 48-72 h. The  expression of IGF-I mRNA 
is accompanied by a 2.5-fold accumulation of IGF-I in 
the  culture medium. IGF-I receptors  also  increase tran- 
siently,  doubling by 48 h after  the onset of differentia- 
tion. By contrast,  secretion of a M, 29,000 IGF binding 
protein is induced 30-fold to 100 ng/ml within 16 h 
and continues to  increase  throughout  differentiation. 
These studies demonstrate that several components 
critical  to IGF action are produced  in a fusing  skeletal 
muscle cell  line in a  differentiation-dependent  manner 
and suggest that  both IGF-I and IGF-I1 may be  auto- 
wine factors  for muscle. 
* This work was funded in  part by National Institutes of Health 
Grants DK37449, HD20805, and HL36313 and by the Basil O’Connor 
Starter Research Grant 5-639 from the March of Dimes Birth Defects 
Foundation (to  P. R.). The costs of publication of this article were 
defrayed in  part by the payment of page charges. This article must 
therefore be hereby marked “advertisement” in accordance with 18 
U.S.C. Section 1734 solely to indicate this fact. 
DK07120. 
ll Supported by National Institutes of Health Training Grant 
$4 To whom correspondence should be addressed Washington 
University School of Medicine, Box 8127, 660 S. Euclid Ave., St. 
Louis. MO 63110. 
The insulin-like  growth factors  (IGFs)’ I and I1 are  struc- 
turally  similar polypeptides with diverse biological properties 
(for review, see Refs. 1-3). Like  other  multifunctional  peptide 
growth factors (4), the  IGFs  stimulate cellular  replication and 
exert  other effects not  directly  related  to cell growth (2, 5- 
11). In myoblasts, IGF-I and IGF-I1 have been shown to 
enhance both proliferation and differentiation (12, 13), to 
promote  nutrient  uptake,  and  to  inhibit  protein breakdown 
(14-16). Many of the  actions of IGFs  on muscle appear  to be 
mediated by the IGF-I receptor (16, 17), a ligand-activated 
tyrosine-specific protein kinase structurally related to the 
insulin receptor (18). In contrast, the role of the IGF-I1 
receptor in IGF signaling is unclear, despite the apparent 
identification of this glycoprotein as the  cation-independent 
mannose  6-phosphate  receptor involved in  targeting lysoso- 
mal enzymes (19-22). An additional complexity in  determin- 
ing  the  actions of IGFs in many tissues is the presence of 
binding  proteins.  Several cell types  including  myoblasts  have 
been shown  to  secrete  IGF  binding  proteins (23), and  at  least 
one  binding  protein  appears  capable of enhancing  the  mito- 
genic actions of IGF-I  on  fibroblasts  and  smooth muscle cells 
(24). 
We have demonstrated recently the endogenous  expression 
of both  IGF-I1  and  its  receptor  in a myogenic cell line, C2, in 
a differentiation-dependent  manner (25).  Because several 
studies  have suggested that  IGF-I  plays a key role in muscle 
growth (12, 13, 26, 27), we now have  examined  C2 cells for 
other components of IGF signaling. We report here that 
during myoblast differentiation  IGF-I is produced by C2 cells, 
that  the  IGF-I  receptor  is expressed  coordinately, and  that a 
single IGF  binding  protein of M, 29,000 is rapidly  secreted. 
These  observations suggest that  both  IGF-I  and  IGF-I1  may 
be autocrine growth factors for skeletal muscle and that 
muscle differentiation may  provide a useful model for  eluci- 
dating  the  mechanisms by which the  actions of these growth 
factors  are  integrated  within  the cell. 
EXPERIMENTAL PROCEDURES 
Materials-Restriction endonucleases, DNA and RNA polymer- 
ases, DNA ligase, and  other enzymes were purchased from commercial 
suppliers  (Promega  Biotec, New England Biolabs, Bethesda  Research 
Laboratories,  United States Biochemical Corp., and  Stratagene Clon- 
ing  Systems). All deoxynucleotide, dideoxynucleotide, and ribonucle- 
otide triphosphates were obtained from Pharmacia  LKB Biotechnol- 
ogy Inc. Nitrocellulose filters and sheets were from Schleicher & 
The abbreviations used are: IGF,  insulin-like growth factor; 
DMEM, Dulbecco’s modified Eagle’s medium; BSA, bovine serum 
albumin; SDS, sodium dodecyl sulfate;  MOPS, %(N-rnorpho- 
1ino)propanesulfonic acid; HEPES, N-2-hydroxyethylpiperazine-N’- 
2-ethanesulfonic acid. 
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Schuell. Radionuclides (NalZ51, [ c Y - ~ ' P ] ~ A T P ,  [ C Y - ~ ~ P I ~ C T P ,  [ c Y - ~ ~ S ]  
U T P ,   [ C Y - ~ ~ P J C T P )  were purchased from Amersham  Corp. and Du 
Pont-New England  Nuclear. Plasmid Bluescript was obtained  from 
Stratagene. Recombinant [Thr59]IGF-I was purchased from Amgen 
Biologicals, and recombinant  IGF-I1 was generously provided by Dr. 
M. M. Smith (Eli Lilly and Co., Indianapolis, IN). Disuccinimidyl 
suberate was obtained from Pierce Chemical Co. Sera for tissue 
culture (fetal and  neonatal calf serum and horse serum) were pur- 
chased from Bethesda  Research  Laboratories-Gibco. 
Cell Cultures-The mouse C2 cell line (28) was plated at  3 X lo3 
cells/cm2 on gelatin-coated  tissue culture  plates  and grown in DMEM 
supplemented with 10% fetal bovine serum and 10% newborn calf 
serum at 37 "C in humidified 5% Con, 95% air atmosphere. The cells 
reached 90% of confluent  density after 48 h and were harvested as 
undifferentiated cells. To induce differentiation, cells were washed 
with DMEM,  and  the medium was changed to  DMEM plus  2%  horse 
serum. In initial experiments, DMEM with 10% horse serum gave 
equivalent  results. Cells and/or media were harvested at  varying times 
thereafter. Conditioned media were immediately clarified by low 
speed centrifugation and were stored in aliquots at  -80 "C until 
assayed. 
Isolation of Recombinant Bacteriophage Containing  the Mouse IGF- 
I Gene-Approximately 5 X lo5 bacteriophage  plaques  from  a genomic 
library in X Charon 28 (29) were screened by standard methods  (30), 
using  a  32P-labeled (31) rat  IGF-I cDNA (32) as  a  hybridization probe. 
DNA was isolated (33) from plaque-purified positive bacteriophage 
and was mapped by digestion with BamHI, EcoRI, and  HindIII, singly 
or in combination, followed by hybridization  (34) to 32P-labeled rat 
Nucleotide Sequence Analysis-Subclones containing mouse IGF-I 
exons were prepared in plasmid  Bluescript for DNA sequencing  using 
dideoxy chain-terminating  inhibitors  (35). All sequence information 
was verified on both DNA strands. 
RNA Isolation-Total cellular RNA was extracted from prolifer- 
ating  or differentiating C2 cells using  a modified protocol employing 
guanidinium  thiocyanate (36).  The integrity of each RNA sample was 
verified by gel electrophoresis, and the quantity was determined 
spectrophotometrically. 
RNA Analysis-Northern blots were performed following standard 
procedures (37). Total RNA (10 pg) was separated by size in a 1% 
agarose gel containing 2.2 M formaldehyde in 20 mM MOPS,  pH 7.0, 
5 mM sodium acetate,  and 1 mM EDTA. Following capillary transfer 
to nitrocellulose and baking for 3  h at  80 "C in a vacuum oven, the 
filters were prehybridized overnight at  42 "C in buffer containing 50% 
formamide (37). Hybridization to a  32P-labeled canine  creatine kinase 
cDNA (38) proceeded for 18 h a t  42 "C. Post-hybridization washes 
followed standard protocols (37). The filter was exposed to Kodak 
XAR5 film using intensifying  screens for 20 h. 
A  solution  hybridization-nuclease  protection  assay  using 8 pg of 
total RNA was performed as described previously (25). The assay 
included 1.5 X lo6 dpm of a single-stranded mIGF-I exon 3 probe 
synthesized as  an "antisense" transcript (25) from a linearized plas- 
mid using T, polymerase, [cY-~'P]CTP (800 Ci/mmol), and unlabeled 
ATP,  GTP,  and  UTP (see Fig. 1). In several experiments,  a mouse 
IGF-I1 exon 3 probe was similarly employed as described previously 
(25). In all  experiments, adult  or  neonatal mouse liver RNA and yeast 
tRNA were included as positive and negative controls, respectively. 
The latter did not hybridize to either mouse IGF probe. Relative 
RNA abundance was calculated  with  a  scanning  laser  densitometer 
(Pharmacia  LKB Biotechnology Inc.) from autoradiographs of dried 
gels. 
IGF-I Binding Studies-IGF-I was radioiodinated using lactoper- 
oxidase (39) and was stored in 0.1 N acetic acid containing 10 mg/ml 
BSA at -70 "C. The specific activity ranged from 183.8 to 237.6 pCi/ 
pg. Binding  studies were performed as described previously (25, 40). 
Cell monolayers were washed three times in serum-free DMEM 
separated by 20-min incubations at  37 "C. Washed cells were then 
scraped from the  plates with a rubber policeman, centrifuged, and 
resuspended in binding buffer (20 mM imidazole-HCl, pH 7.4, 250 
mM NaCl, 5% glycerol, and 2.5 mg/ml BSA). Cells were added to 1.5- 
ml microcentrifuge tubes  containing 1251-labeled IGF-I and increasing 
amounts of unlabeled IGF-I (final volume 300 rl). After an overnight 
incubation at  4 "C, the cells were centrifuged for 5 min, and the 
supernatant fluid was removed by aspiration.  The cells were washed 
once with 1 ml of binding buffer, and  the pellet was counted.  Binding 
data were analyzed by LIGAND (41). An aliquot of cells equal to  that 
used in the binding  assays was solubilized with 0.5 ml of 0.1% SDS 
for protein determination  (42). 
IGF-I cDNA (34). 
three  times with 20 ml of HEPES buffer (20 mM HEPES, pH 7.4, 
Affinity Cross-linking Analysis-Cell monolayers were washed 
120 mM NaC1, 5 mM KCl, 1.2 mM MgS04, 10 mM NaHC03, 1.3 mM 
CaCI,,  1.2 mM KHzP04)  containing 10 mg/ml BSA. lZ5I-Labeled IGF- 
I (final concentration 0.2  nM) with or without  unlabeled ligand was 
added to  the cells in 12.5 ml of HEPES  buffer  containing 10 mg/ml 
BSA. The cells were incubated  for  4  h a t  15 "C and  then were washed 
with 20 ml of ice-cold phosphate-buffered saline. Disuccinimidyl 
suberate (final concentration 0.1 mM) in 12.5 ml of HEPES buffer 
was added for 20 min a t  15 "C to cross-link the bound ligand. The 
reaction was quenched by the addition of three volumes of 10 mM 
Tris-HC1, pH 7.4, with 1 mM EDTA for 20 min. After aspiration of 
buffer, the cells were scraped from the  plates with  a  rubber policeman 
and centrifuged. The cell pellets were solubilized in 200 rl of electro- 
phoresis sample buffer containing 2% SDS with or without 5% 2- 
mercaptoethanol. SDS-polyacrylamide gel electrophoresis was per- 
formed according to  the method of Laemmli (43).  Autoradiographs 
were obtained by exposure of the dried gels to Kodak XAR5 x-ray 
film in  the presence of a Du Pont Cronex  Lightning Plus intensifying 
screen a t  -70 "C. Molecular weight standards include myosin ( M ,  
200,000), @-galactosidase ( M ,  116,2501, phosphorylase b ( M ,  97,4001, 
and BSA ( M ,  66,200). 
Binding Protein Assay-The binding protein content of condi- 
tioned media was determined by measuring the ability of aliquots to 
bind '251-labeled IGF-I (23). Media were incubated a t  20 "C for 1 h 
with 20,000 cpm of 'z51-labeled IGF-I in 250 pl of buffer (100 mM 
HEPES,  pH 6.0, 44 mM NaH2P04, 0.01% Triton X-100, 0.1 mg/ml 
BSA, 0.02% NaNJ. Complexes of binding protein and IGF-I then 
were precipitated by the addition of 250 pl of 1% human immune 
globulin and 500 p1 of 25% polyethylene glycol, followed by centrifu- 
gation at  1,200 X g for 15 min. The pellet was washed once with 
6.25% polyethylene glycol and counted. Results are expressed as 
nanograms of binding  protein/milliliter of conditioned media. Pure 
human amniotic fluid binding protein was used as a standard.  The 
assay has a lower limit of detection of 50 pg of pure  standard (23). 
Ligand Blotting-A 21-pl aliquot of conditioned  media was mixed 
with  7 pl of 4 X concentrated Laemmli  (43)  sample buffer without 2- 
mercaptoethanol and heated to 60 "C for 10 min before being  applied 
to a 12.5% discontinuous SDS-polyacrylamide gel. Samples were 
electrophoresed at  20 mA until  the dye front reached the  bottom of 
the gel (1.5 h). Proteins were transferred to a nitrocellulose filter 
using a semidry electroblotter at  70 mA for 1 h as described by 
Hossenlopp et al. (44). The filters were probed for IGF binding 
proteins  with 400,000 cpm of '251-labeled IGF-I. Binding proteins  then 
were visualized by autoradiography. Molecular weights were esti- 
mated by comparison to  prestained  protein  standards electrophoresed 
in adjacent lanes of the gel. 
Radioimmunoassay-Media were acidified by adding an equal vol- 
ume of  0.5 N HCl and were passed through a C,, cartridge (Sep-Pak, 
Waters Associates). The cartridge was washed with  10 ml of  4% acetic 
acid, and IGFs were eluted  using  7 ml  of 50% acetonitrile in distilled 
Hz0 (45). Aliquots were lyophilized and reconstituted in immunoas- 
say buffer (46). Under these conditions  binding proteins do not  elute 
from the column and recovery of added lZ5I IGF-I is -80%,, Rabbit 
anti-human somatomedin C/IGF-I antibody  (47),  lot UBK487, from 
the National Hormone and  Pituitary Program (kindly provided by 
Drs. J. J. Van Wyk and L. E. Underwood, University of North 
Carolina,  Chapel  Hill, N.C.) was used in  the radioimmunoassay. With 
human recombinant [Thr5']IGF-I as  standard  and  tracer, cross-re- 
activity  with  IGF-I1  is -0.5%. 
RESULTS 
Identification of the Mouse IGF-I Gene-Two recombinant 
bacteriophage were isolated and purified from the mouse 
genomic library by hybridization to a rat IGF-I cDNA. The 
two clones contained overlapping inserts of murine DNA. The 
mouse equivalents of rat  and  human  IGF-I exons 3 and 4 (48, 
49) were identified by blot hybridization (34), as indicated  in 
Fig. lA. Fig. 1B illustrates  a higher resolution restriction map 
of exon 3 and depicts the 870-base pair probe used in subse- 
quent studies. The sequence of exon 3 is shown in Fig. IC. 
This exon encodes the carboxyl part of the B domain of 
S. E. Tollefsen, R. Lajara, R. H. McCusker, D. R. Clemmons, and 
P. Rotwein, unpublished  observations. 




5' - 3' 
Exons 3 4  
BomHI I I 
EcoRI I I  I I I  I I  




Bom H I  EXON 3 EcoRI 
H 
c I 
mIGF1 Exon 3 probe ' 
C. 
~ ~ ~ ~ . . C . C C . ~ C C C I ~ ~ C I ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ C T C C ~ C C A T T C G G ~ G G G C ~ C C T C ~ G A C ~ G G C A T T C T G G ~ T  
.nL~.,'Olh,Cl~T~rCI"L..5.rIl.Lrq~rq~l.*.oOlaTh.Cl~1l.~.IL.p 
C h G T C T T G C T T C C G C l G C T G T G * T C T G I C C I C I C T C B I C I A C ~ ~ A A C C A G C C C C C T ~ T ~ T ~ ~ C T C C C  
C l u C ~ ~ C ~ a l h ~ ~ ~ ~ S ~ ~ C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ l ~ ~ ~ ~ L ~ ~ L q ~ ? ~ ~ T ~ ~ L q ~ ~ l ~ A l ~ ~ ~ q ~ ~ ~ L l ~ l r g ~ l ~  
C h G C G C C * C I C T T * C I T C C C ~ * * ~ ~ ~ * ~ ~ ~ ~ ~ ~ ~ ~ . = ~ " ~ = ~ . ~ ~ ~ ~ ~ ~ ~ . . . , = ~ ~ ~ ~ ~  
G i n * . q l l , . . T h r * ; . ~ . l F l D L I r T h r G l n L y i  
FIG. 1. Partial  characterization of the mouse IGF-I gene. A, 
part of the 3' end of the gene is illustrated. Exons 3 and 4 are depicted 
by boxes. The cross-hatched portion within exon 4 has not been 
characterized fully. Sites for restriction endonucleases RamHI, 
EcoRI, and Hind111 are indicated below the gene, as are two X clones. 
R, a detailed map of  exon 3 is shown. The 870-base pair (bp)  probe 
used in gene expression studies extends from a 5' RamHI site  to a 3' 
EcoRI site. C, the DNA sequence of exon 3 is illustrated. Introns are 
in lowercase and the exon  in uppercase letters. The amino acid 
sequence encoded by exon 3 appears below the corresponding DNA. 
Bold type highlights the part of the mature IGF-I peptide encoded by 
this exon. kb, kilobase pair. 
mature  IGF-I,  as well as  the  entire C, A, and D regions, as 
indicated by the boldface type. The  16  amino-terminal residues 
of the E domain of the  IGF-I  precursor  comprise  the 3' end 
of the  exon, as depicted by regular type. The nucleotide and 
derived amino acid  sequence of exon 3 presented  here  match 
data previously obtained by others (50,  51). 
Analysis of IGF Gene Expression in Differentiating Muscle 
Cells-To determine  whether muscle cells  produce IGF-I, we 
analyzed the myogenic cell line C2 for IGF-I mRNA. This 
cell line provides  a convenient model for studying  gene  expres- 
sion  during  both  myoblast  proliferation  and  differentiation. 
Contracting  myotubes  form  within 96-120 h after  triggering 
the  differentiation program  by changing  the cell culture me- 
dium to DMEM with 2 or 10% horse  serum (see Fig. 2). Total 
cellular RNA,  obtained a t  various  times  during C2 differen- 
tiation, was examined by a sensitive  solution  hybridization- 
nuclease protection  assay  using  the  probe  depicted  in Fig. 1B. 
As illustrated  in Fig. 3A, a minimal  amount of IGF-I  mRNA 
was  detected  in  proliferating  myoblasts  and  during  the  initial 
24 h of terminal  differentiation  into myotubes.  By 48  h, levels 
of IGF-I  mRNA  increased  dramatically (15-fold in  this  exper- 
iment) but then declined over the ensuing 72 h. By 120 h 
when cells are fully differentiated,  the  IGF-I  mRNA level was 
only  three  times higher than  that  found  in  proliferating myo- 
blasts. As shown  in  the right panel of Fig. 3, data  obtained 
from eight  similar  experiments  (two  studies  on  each of four 
sets of differentiating cells) support  the  results  illustrated  in 
Fig. 3A. IGF-I  mRNA  peaked  transiently between 48  and 72 
h after  the  onset of differentiation at 6-10 times  the level 
found  in undifferentiated cells. In  contrast  to  the  transitory 
expression of IGF-I  mRNA,  mRNA  for muscle-specific  genes 
such  as  creatine  kinase  accumulated  during  myoblast differ- 
entiation (Fig. 3B) .  
We  have  shown  previously that  IGF-I1  mRNA  also  is  in- 
. . .. 
FIG. 2. Differentiation of C2 cells into myotubes. The top 
panel shows C2 myoblasts at the end of their proliferative phase. The 
cells are at approximately 90% of confluent density. The middle panel 
illustrates the extent of myogenesis after 48 h in differentiation 
medium as described under "Experimental Procedures." Cell fusion 
and the formation of myotubes has begun. The bottom  panel shows 
the  extent of differentiation by 96 h. Giant myotubes have developed. 
All phase contrast photomicrographs were obtained at X 90 magnifi- 
cation and depict the same field of cells. 
duced in C2 cells with  differentiation-dependent  kinetics  and 
that IGF-I1 is  secreted  into  the  culture medium of differen- 
tiating  myoblasts  (25).  In  order  to  compare  the  abundance of 
each growth factor  during muscle differentiation, we exam- 
ined  the relative levels of both  IGF  mRNAs  and measured 
both  peptides  in  conditioned  culture medium. The  mRNAs 
were analyzed  by  employing IGF-I  and IGF-I1 probes simul- 
taneously in the solution hybridization-nuclease protection 
assay. As depicted  in Fig. 4, RNA from adult  and  neonatal 
liver and from C2 cells protected a 182-nucleotide fragment 
of the mouse IGF-I  exon 3 probe. Steady-state levels of IGF- 
I mRNA  are higher in  adult  than  in  neonatal liver, consistent 
with  the  known  postnatal  increase  in  IGF-I gene  expression 
in mice (51, 52). There  is  also  an  increase  in  IGF-I mRNA 
during  C2  differentiation  similar to  what was illustrated  in 
Fig. 3A. RNA  from  neonatal,  but  not  adult liver, protected a 
151-152-nucleotide fragment of the IGF-I1 exon 3 probe as 
described previously (25). In C2 cells, there is a dramatic 
increase  in IGF-I1 mRNA  during  differentiation (>25-fold in 
this  experiment),  consistent  with  our previous results (25). 
The  relative  abundance of IGF-I1  mRNA at 72 h after induc- 
tion of differentiation is a t  least 15 times higher than  the 
level of IGF-I  mRNA based on  densitometric  scanning of the 
autoradiograph  presented  in Fig. 4. Results from  radio- 
immunoassay of conditioned  culture medium corroborate  the 
mRNA measurements. As shown in Fig. 5, radioimmuno- 
assayable  IGF-I  increases by 250% during  the  initial 72 h of 
differentiation  and  then declines  slightly. The  apparent rise 
a t  120  h  may  reflect slight  cross-reactivity  in  the  assay  with 
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FIG. 3. Detection of  IGF-I mRNA in differentiating C2 cells. Total cellular RNA was isolated a t  various 
intervals  after  exposure of cells to  differentiation medium as described under  “Experimental Procedures.” Left 
panel: A, RNA (8 pg) was  subjected to a solution hybridization assay  using  the  IGF-I  exon 3 probe  (see Fig. 1B). 
Autoradiographic  exposure  time was for 36 h. The “protected” 182 nucleotide ( n t )  fragment  is  indicated. B, an 
autoradiograph of an RNA blot  hybridization  experiment  is  illustrated  using 5  pg of the  RNA used in A and a 
canine  creatine  kinase probe. Autoradiographic  exposure  time was for 16 h. The appearance of creatine  kinase 
mRNA is an  indicator of myogenic differentiation in these cells. C, the  RNA gel used in  the  experiment  pictured 
in B is  shown  (photographed  under  ultraviolet  light  after  staining  the gel with ethidium  bromide).  Positions of 28 
S and 18 S rRNA  are indicated  for B and C.  Right panel: the  bar  graphs  depict  the relative levels (mean zk S.E.) of 
IGF-I  mRNA observed during C2 differentiation (n = 8 experiments,  two for each of four  sets of differentiating 
cells). Data were obtained  using a scanning  laser  densitometer  and have  been  normalized to  the  values  obtained a t  
48 h after  the start of differentiation, which has been set  arbitrarily  to 10. 
c2 - 
0 72hr tRNA 
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FIG. 4. Detection of IGF-I and IGF-I1 mRNA in differen- 
tiating C2 cells. Total  cellular  RNA was  isolated a t  varying  intervals 
after exposure of cells to differentiation medium as described under 
“Experimental Procedures.”  RNA (8 pg)  was  subjected to a solution 
hybridization  assay simultaneously  using equal amounts of IGF-I  and 
IGF-I1  probes  labeled to the  same specific  activity. Autoradiographic 
exposure time was  for  12 h. Protected  fragments of 182 nucleotides 
(nt)  (IGF-I)  and 151-152 nucleotides (IGF-11) are  indicated. 
IGF-I1 because IGF-I1  accumulates in  the media to more than 
1000 ng/lO ml at  this time. Thus,  although  both  IGF-I  and 
IGF-I1 mRNA and  protein secretion  increase during C2  dif- 
ferentiation,  the expression of IGF-I1  is a t  least  an  order of 
magnitude  greater than IGF-I. 
Analysis of  the IGF-I Receptor in Differentiating C2 Cells- 
To determine if C2 cells express IGF-I receptors on their 
surface, IGF-I  binding  to  undifferentiated  and  differentiating 
cells was examined in competition binding studies. Fig. 6A 
shows Scatchard plots of data from a representative study. 
The  Scatchard  plots of IGF-I  binding to undifferentiated cells 
and  to cells harvested 24-96 h after induction of differentia- 
SI 24 llln 48 72 96
Tame in Differentiation Medium (hrs) 
FIG. 5. Secretion of IGF-I and IGF-I1 during C2 differen- 
tiation. Conditioned  culture medium was collected a t  varying inter- 
vals after  exposure of cells to differentiation medium (DMEM  plus 
2% horse  serum),  and  radioimmunoassays for IGF-I  and IGF-I1 were 
performed as described under  “Experimental Procedures.” The mean 
IGF-I levels (measured  in  triplicate) from one of three  representative 
experiments  are depicted at   the indicated  time  points by the cross- 
hatched bars. IGF-I1  levels (25)  are  indicated by the solid bars. The 
levels of IGF-I and IGF-I1 in nonconditioned 2% differentiation 
medium  ranged  from 8 to  14 ng/lO ml, and  from 30 to 55 ng/lO ml, 
respectively. 
tion  are linear. In  this  experiment  undifferentiated C2 cells 
bound 0.178 pmol of IGF-I/mg  protein,  and cells harvested 
72 h after  induction of differentiation  bound 0.464 pmol of 
IGF-I/mg protein.  Analysis of data  obtained from seven in- 
dependently performed experiments indicates that  the xpres- 
sion of the IGF-I receptor on the cell surface of C2 cells 
increases transiently,  but significantly, during differentiation, 
as illustrated in Fig. 6B. The number of IGF-I receptor 
binding sites in cells harvested 48-72 h after induction of 
differentiation is about two times higher than  in undifferen- 
tiated cells, although  there is some variability among  different 
experiments.  Correction of the  data for protein  content, as 
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FIG. 6. IGF-I binding to undifferentiated  and  differentiat- 
ing C2 cells. IGF-I binding studies were performed as described 
under  “Experimental Procedures.” A, Scatchard  plots of IGF-I bind- 
ing to cells  harvested 48 h after  initiation of growth (0) or 72 h after 
induction of differentiation (W). Binding assays contained 45,000 cpm 
(0.062 nM)  of ’251-labeled IGF-I and 0-1 pg/ml (0-130.8 nM)  of 
unlabeled IGF-I in  a final volume of 300 pl. Each  point  represents 
the mean of duplicate  assays.  Binding data were analyzed by LIGAND 
(41). N ,  the  ratio of nonspecifically  bound  ligand to free  ligand, was 
0.0029 and 0.0095 for undifferentiated  and  differentiating C2 cells, 
respectively, and nonspecific binding, N X F, has been subtracted. 
The solid lines are  computer-generated  best fits for a one-site  binding 
model. The binding capacities and dissociation constants for IGF-I 
binding  to  undifferentiated  and  differentiating cells in this experi- 
ment  are 0.042 and 2.3 nM and 0.189 and 3.51 nM, respectively. Data 
have not been adjusted for protein  content  in  this  study (71.2 pg/ 
assay  for undifferentiated cells and 122.0 pg/assay  for differentiating 
cells). B, IGF-I receptor  expression during muscle differentiation. C2 
cells were harvested 48 h after  initiation of growth (0  h)  or 24-96 h 
after induction of differentiation as indicated. Data have  been  cor- 
rected  for protein  content of cells  in each assay. The IGF-I binding 
capacity (mean f S.E.) obtained a t  each time point (n = 3-6) in 
seven independently  performed experiments  and  the IGF-I1 binding 
capacity (mean f S.E.) a t  0 and 72 h (25) are depicted by cross- 
hatched and closed bars, respectively. **, p < 0.02; *, p < 0.01 versus 
time 0 h for IGF-I binding capacity; A, p < 0.001 versus time 0 h  for 
IGF-I1 binding  capacity (Student’s t test). 
presented  in Fig.  6B, may underestimate the magnitude of the 
increase in receptor number which occurs during  differentia- 
tion because total protein content of C2 cells also increases? 
The dissociation constants  (means & S. D.) of IGF-I binding 
to undifferentiated and  to differentiating C2 cells are 3.29 & 
1.26 nM (n  = 7) and 3.71 f 1.35 nM (n = 15), respectively, 
indicating that  the affinity of the receptor for IGF-I does not 
change during  differentiation. As reported previously (25), the 
number of IGF-I1 receptor binding sites is increased 8.7-fold 
in C2 cells harvested 72 h after induction of differentiation. 
In  contrast, insulin binding to undifferentiated C2 cells and 
to cells studied 48 h after the onset of differentiation is 
negligible.2 
To confirm that  the receptor to which IGF-I  binds  in these 
cells is the authentic IGF-I receptor, affinity cross-linking 
studies were performed (Fig. 7). ’251-Labeled IGF-I was cross- 
linked predominantly to proteins which migrated under  non- 
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FIG. 7. Affinity cross-linking of IGF-I to C2 cells. C2 cells 
were incubated for 4 h a t  15  “C with 1251-labeled IGF-I (0.2 nM) in 
the absence (lanes I )  or presence of 100 ng/ml of either unlabeled 
IGF-I (lanes 2), unlabeled IGF-I1 (lanes 3), or unlabeled insulin 
(lanes 4 ) .  Affinity cross-linking was  performed  with 0.1 mM disuccin- 
imidyl suberate as described under  “Experimental Procedures.” 
Shown are autoradiographs of the radioligand-receptor complexes, 
analyzed by SDS-polyacrylamide gel electrophoresis. A, 3-10% acryl- 
amide gradient resolving gel under nonreducing conditions; E ,  5% 
acrylamide resolving gel under reducing  conditions. The migration of 
molecular weight standards is  indicated. 
(Fig. 7A, lane 1 ) .  These proteins  correspond to  the (a@)*, the 
(CUB) (a@‘), and  the ( c u @ ’ ) ~  forms of the IGF-I receptor (53). 
After reduction with 2-mercaptoethanol, these complexes mi- 
grated with an  apparent M, 135,000 (Fig. 7B, lanes l ). Cross- 
linking of 1251-labeled IGF-I was markedly inhibited in the 
presence of unlabeled IGF-I  (lanes 2), was  weakly inhibited 
by unlabeled IGF-I1 (lanes 3), and was not inhibited by 
unlabeled insulin  (lanes 4 ) .  These results agree with previous 
IGF-I receptor cross-linking analyses (53) and demonstrate 
that IGF-I interacts specifically with the IGF-I receptor on 
the surface of C2 cells. In C2 cells, the IGF-I1 receptor is 
detected only after cross-linking with 12sI-labeled IGF-I1 (25). 
Analysis of IGF Binding Proteins in Differentiating C2 
Cells-To determine  whether muscle cells secrete specific IGF 
binding  proteins, ligand blots and IGF  binding  assays were 
performed using  conditioned medium from undifferentiated 
and differentiating C2 cells. As illustrated  in the ligand blot 
shown in Fig. 8A, medium collected from undifferentiated 
cells contains  little  IGF binding  activity.  During C2 differen- 
tiation a  binding  protein of M ,  29,000 appears. This binding 
protein is not seen in nonconditioned culture medium with 
2% horse serum? By densitometric analysis of the autoradi- 
ograph pictured  in Fig. BA, binding protein  increases 4-fold 
within  4  h, 30-fold by 16 h, and 100-fold by 120 h after  the 
onset of C2 differentiation (Fig. BA, bottom panel). An in- 
crease  in  binding  protein accumulation also is seen  in  deter- 
gent extracts of cell pellets.2 
The binding capacity of conditioned culture medium for 
1251-labeled IGF-I rises rapidly during C2 differentiation and 
reaches 100 ng/ml by 16 h (Fig. 8B). By 48 h, binding capacity 
has decreased and remains low throughout the remainder of 
the  time course. Although these observations appear to con- 
tradict  the results observed with ligand blotting,  in which a 
continual rise in  IGF binding protein is seen, the decline in 
binding  capacity  coincident with an increase in total binding 
protein content can be explained by occupancy of binding 
protein with endogenously produced and secreted ligand. The 
kinetics of secretion of IGF-I1 by differentiating C2 cells 
appear to match the decline in binding activity observed here 
(see Fig. 5 and Ref. 25). Thus,  the binding assay corroborates 
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FIG. 8. Detection of IGF binding  proteins  in  differentiating 
C2 cells. A, ligand blot showing binding of ’2sII-labeled IGF-I to 
proteins found in conditioned culture medium. Medium (21 P I )  from 
C2 cells was subjected to SDS-polyacrylamide gel electrophoresis. 
Proteins were transferred to a nitrocellulose filter using a semidry 
electroblotter, and filters were probed for IGF binding proteins as 
described under “Experimental Procedures.” The autoradiograph 
shown here depicts a predominant protein of M, 29,000, which, as 
illustrated in the accompanying bar graph, increases >lOO-fold in 
intensity during C2 differentiation. B,  IGF binding activity of con- 
ditioned culture medium was assessed by measuring the ability of 
aliquots to bind ‘2sI-labeled IGF-I. Binding content increases to 100 
ng/ml within 16 h after the start of differentiation but declines by 48 
h, probably because endogenously synthesized and secreted IGF-I1 
also accumulates in the medium and occupies binding sites  (see Fig. 
5 and Ref. 25). 
data  obtained by radioimmunoassay on  the  differentiation- 
dependent secretion of IGF-I1 by  C2 cells (25). 
DISCUSSION 
This  study  demonstrates  that several components involved 
in modulating IGF activity are regulated in a fusing skeletal 
muscle cell line  in a differentiation-dependent  manner.  IGF- 
I  mRNA transiently increases during myogenesis, and  IGF-I 
accumulates in conditioned culture medium, although to less 
than 5% of the level of IGF-11. IGF-I receptor affinity is 
similar  in  undifferentiated myoblasts and fully differentiated 
myocytes but receptor number increases transiently by about 
%fold during differentiation. In contrast, IGF-I1 receptor 
expression, which is  less than 50% of IGF-I receptor  expres- 
sion in  undifferentiated myoblasts,  increases  markedly during 
myogenesis and  remains high. An IGF  binding  protein of M, 
29,000 accumulates rapidly in conditioned culture media of 
differentiating C2 cells. Binding  protein levels measured by a 
ligand blotting technique increase by 100-fold during my- 
ogenic differentiation. The inducible nature of IGF ligand, 
receptor, and binding protein expression during C2 differen- 
tiation suggests that  both  IGF-I  and IGF-I1 may function as 
autocrine  factors  in muscle. 
The signals that modulate IGF-I gene expression during C2 
differentiation are unknown. The  best  characterized regulator 
of IGF-I is growth hormone, which rapidly increases IGF-I 
transcription  in whole animals  and  in  certain cell lines (51, 
54-57). Growth hormone probably does not play a role in 
IGF-I gene expression in C2 cells because its content in 
differentiation medium is negligible ((0.01 nM), and  addition 
of growth  hormone to a final concentration of 5 nM does not 
alter  the  abundance of IGF-I or IGF-I1  mRNA during differ- 
entiation.’ In  animals,  additional signals modify IGF-I mRNA 
abundance.  In  early  rodent development, IGF-I mRNA in- 
creases  nearly 10-fold between embryonic days 11 and 13 (58), 
several days prior to  the ontogeny of growth  hormone synthe- 
sis  and secretion by the  pituitary  and before the  appearance 
of cell surface receptors for growth hormone (59, 60). In 
addition, in adult rats, nutritional factors modify levels of 
IGF-I  mRNA in liver independent of growth hormone  (61). 
Whatever  the mechanisms responsible for the induction of 
IGF-I gene expression during muscle development in C2 cells, 
the signal that is  generated  is transitory,  and  the secretion of 
IGF-I is  modest,  being  markedly less than  that of  IGF-11. 
The signals that  alter expression of the  IGF-I receptor and 
the  IGF  binding  protein  during differentiation are similarly 
unknown. In  the  human IM-9 lymphoid cell line, in  human 
fibroblasts, and in the mouse BC3H-1 myoblast cell line, 
preincubation with  IGF-I, IGF-11, or  insulin  leads to down- 
regulation of the  IGF-I receptor,  resulting from a decrease in 
receptor number (62). In addition, in a t  least  one subclone of 
the  rat L6 myoblast cell line, binding of IGF-I declines by 
about 70% 18 days after  the  onset of differentiation (14). In 
contrast, secretion of IGF binding proteins by rat L6 myo- 
blasts and myotubes is enhanced by exposure of cells to 
pharmacological concentrations of insulin (1 pg/ml). How- 
ever, following differentiation there i s  a significant loss in 
sensitivity to insulin stimulation (23). In  both  BC3H-1  and 
L6 cells, IGF-I  enhances binding protein secretion, with half- 
maximal stimulation between 12 and 24 ng/ml. These cells 
respond to IGF-I with increased binding protein secretion 
regardless of their  state of differentiation  (63). In C2 cells, it 
is  unlikely that insulin,  IGF-I, or IGF-I1 modify cell surface 
levels of the IGF-I  receptor or trigger secretion of the  IGF 
binding  protein  that is  seen shortly  after  the cells are placed 
in differentiation medium because concentrations of these 
ligands in growth and  in  differentiation medium are low (30- 
50 pg/ml for insulin, 1-3 ng/ml for IGF-I, and 3-5 ng/ml for 
IGF-11). However, by 72 h after  the  onset of differentiation 
when there is substantial  induction of IGF-I1(25),  this peptide 
could stimulate binding protein secretion or down-regulate 
the  IGF-I receptor. These  findings suggest that  the  dramatic 
induction in  IGF  binding  protein  that precedes the increase 
in IGF-I or IGF-I1  may be linked  to  early  events  in muscle 
differentiation. 
What  are  the  potential  functions of IGF-I  and IGF-I1 in 
muscle that support an autocrine action for these growth 
factors  during myogenesis? Florini et al. (12) have suggested 
that relatively low concentrations of IGF-I (10 ng/ml) or 
moderate  concentrations of IGF-I1 (10-300 ng/ml)  promote 
differentiation of L6 myoblasts. Similar observations have 
been made by Schmid et al. (13) using chick embryo fibro- 
blasts  and myoblasts, although  in  these  studies  subnanomolar 
concentrations of either IGF enhanced myogenesis. It has 
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been proposed that both growth factors interact with the IGF- 
I receptor which then mediates the differentiative response 
(16, 17). In a similar context, Smith et al. (64) have shown 
that murine NIH  3T3-Ll preadipocytes differentiate into  fat 
cells in response to 10-20 nM IGF-I (85-170 ng/ml) and have 
suggested that activation of the IGF-I receptor occupies a 
central  step in the differentiation process. Other studies in 
L6 myoblasts and  in  intact  rat soleus muscle provide strong 
evidence that IGF-I and IGF-I1  enhance nutrient  uptake  and 
that these  actions  appear to be mediated through the  IGF-I 
receptor (16, 17, 65). In  contrast, in  human myoblasts, IGF- 
I1 appears to be equipotent with IGF-I in  stimulating  uptake 
of the nonmetabolizable amino acid analogue, a-aminoisobu- 
tyric acid and antibodies to  the  IGF-I receptor only inhibit 
about half of the IGF-I1 effect (15). Thus,  the interactions of 
the IGFs with their receptors may produce pleiotropic effects 
in muscle. 
The role of the M, 29,000 IGF binding protein  during muscle 
cell differentiation is not well-defined. Other IGF binding 
proteins, most notably that derived from human amniotic 
fluid (24), appear to potentiate  the mitogenic actions of IGF- 
I on mouse and chicken embryo fibroblasts, human fibro- 
blasts, and porcine aortic  smooth muscle cells at  concentra- 
tions (100 ng/ml) similar to those  that C2 cells produce during 
differentiation. Because the binding protein derived from 
amniotic fluid adheres to  the cell surface, possibly by an Arg- 
Gly-Asp sequence near its carboxyl terminus (66-68), it is 
conceivable that interaction  with  extracellular matrix protein 
receptors, or integrins  (69), modulates binding protein  action 
during myoblast differentiation. In  this context, because an- 
tibodies to  an integrin have been shown to reversibly inhibit 
muscle differentiation (70), the  IGF binding protein described 
here could be a critical factor in induction of myogenesis. 
Additional study of this protein will be required to clarify its 
role in muscle development. 
In summary, we have described the differentiation-depend- 
ent expression and/or modulation of five components  in the 
IGF-I and IGF-I1 signaling pathways in a fusing skeletal 
muscle  cell line. Characterization of the mechanisms of reg- 
ulation and  the modes of action of IGF-I  and IGF-11, their 
receptors, and  their binding proteins in  this model system 
should provide insight into  the processes of cellular differen- 
tiation. 
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